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Oxidative stress plays a critical role in the pathogenesis of intestinal ischemia reperfusion (IIR) injury. Enhancement in endogenous
Lipoxin A4 (LXA4), a potent antioxidant and mediator, is associated with attenuation of IIR. However, the effects of LXA4 on
IIR injury and the potential mechanisms are unknown. In a rat IIR (ischemia 45 minutes and subsequent reperfusion 6 hours)
model, IIR caused intestinal injury, evidenced by increased serum diamine oxidase, D-lactic acid, intestinal-type fatty acid-binding
protein, and the oxidative stressmarker 15-F2t-Isoprostane. LXA4 treatment significantly attenuated IIR injury by reducingmucosal
15-F2t-Isoprostane and elevating endogenous antioxidant superoxide dismutase activity, accompanied with Keap1/Nrf2 pathway
activation. Meanwhile, LXA4 receptor antagonist Boc-2 reversed the protective effects of LXA4 on intestinal injury but failed to
affect the oxidative stress and the related Nrf2 pathway. Furthermore, Nrf2 antagonist brusatol reversed the antioxidant effects
conferred by LXA4 and led to exacerbation of intestinal epithelium cells oxidative stress and apoptosis, finally resulting in a decrease
of survival rate of rat. Meanwhile, LXA4 pretreatment upregulated nuclear Nrf2 level and reduced hypoxia/reoxygenation-induced
IEC-6 cell damage and Nrf2 siRNA reversed this protective effect of LXA4 in vitro. In conclusion, these findings suggest that LXA4
ameliorates IIR injury by activating Keap1/Nrf2 pathway in a LXA4 receptor independent manner.
1. Introduction
Intestinal ischemia reperfusion (IIR), a critical condition usu-
ally caused by many clinical scenarios such as shock, acute
mesenteric ischemia, sepsis, mesenteric thrombosis, or bowel
transplantation [1], is closely related to high morbidity and
mortality [2]. Interruption of blood supply to intestine could
result in tissue damage. However, the subsequent blood flow
restorationmay lead to additional injury, referred to as reper-
fusion injury [3]. During reperfusion, when oxygen is sup-
plied in large amounts to the tissues that is deprived of oxy-
gen, the electrons from xanthine oxidase are transferred to
molecular oxygen, forming large quantities of superoxide
radicals [4]. Thus, far greater amounts of oxidants are pro-
duced after restoration of blood supply to the ischemic tis-
sues.This causes damage to the intestinalmucosa and impair-
ment of the local microvasculature, leading to high perme-
ability of vascular and mucosa breakdown and subsequent
systemic sepsis and multiple organ failure [5], which con-
tributes to a high mortality in the critical care setting. Cur-
rently, effective preventive therapy of IIR injury is lacking.
Due to the great involvement of reactive oxygen species
(ROS) in the pathophysiology of IIR injury, antioxidants
have been employed by researchers in an attempt to alleviate
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the injury caused by IIR [6–8]. Nrf2 is a stress sensing genetic
transcription factor that functions as a master regulator of
cellular responses to oxidative damage and other stressful
conditions [9]. The Nrf2 antioxidant response pathway is
“the primary cellular defense against the cytotoxic effects of
oxidative stress” [10]. Recently, our studies showed that the
Nrf2 pathway took part in intestine ischemia reperfusion
injury and that enhancing Nrf2 nuclear translocation could
effectively attenuate postischemic intestinal mucosal impair-
ment [11]. It, therefore, suggests that increasing endogenous
antioxidative capacity would confer protective effects in
conditions that may cause IIR injury.
Lipoxins (LXs) are members of the family of bioac-
tive products generated from arachidonic acid [12]. These
molecules used to be identified in vivo as the first endogenous
“braking signals” of inflammation [13]. Of note, recent studies
showed that LXs also played an important role in the
prevention of oxidative stress-mediated tissue injury [14–17].
Lipoxin A4 (LXA4) (C
20
H
32
O
5
, Figure 1) is one of the most
important LXs and can bind to the LXA4 receptor (ALXR), a
specific G-protein-coupled receptor [18]. In addition, LXA4
may exert biological effects through othermechanismswhere
the protective effect of LXA4 was found to be partially
mediated by transcription factor peroxisome proliferator-
activated receptors gamma (PPAR𝛾) in experimental brain
ischemia reperfusion in rodents [19]. However, few reports
concern its function on antioxidative stress and its impact
on endogenous antioxidant signaling pathway during IIR in
vivo.
We hypothesized that the antioxidant effects of Lipoxin
A4 are mediated via Nrf2 pathway activation, which may
effectively attenuate IIR injury in the early stage. The cur-
rent study was aimed to investigate whether Lipoxin A4
preconditioning could mitigate intestinal mucosa injury and
increase postischemic survival rate through reducing oxida-
tive stress via activating Keap1/Nrf2 pathway in a rat model
of IIR injury.
2. Materials and Methods
2.1. Animals. Male Sprague-Dawley rats (weighing 200–
250 g) were housed in individual cages in a temperature-con-
trolled room with 12-h light-dark cycles in the Department
of Laboratory Animal Center at SunYat-senUniversity with a
specific pathogen-free (SPF) grade, laminar flow atmosphere.
All animals were fasted overnight before the experiment
but had free access to water. Animal study protocols were
approved by the Sun Yat-sen University Animal Care Com-
mittee, and the experiments were performed in adherence to
the guidelines provided by the National Institutes of Health
for the use of animals in laboratory experiments.
2.2. Intestine Ischemia and Reperfusion. Rats were anes-
thetizedwith pentobarbital (30mg/kg bodyweight) via intra-
peritoneal injection under 50% oxygen delivered using an
animal mask as the previous study [20]. The intestinal
ischemia was established by occluding the superior mesen-
teric artery (SMA) and confirmed by immediate blanching of
the small intestine and cecum. After ischemia for 45 minutes
(min), vascular clamp was removed and SMA was reflowed,
which was recognized by returning to gut’s original color
[21]. During the experiments, temperature of animals was
maintained in normothermia (37∘C) with heating pads. After
reperfusion for 6 hours, rats were sacrificed subsequent to
being deeply anesthetized with chloral hydrate (400mg/kg
body weight, i.p.). The sham group was subjected to the
surgical procedures described below without intestine and
vessel manipulation and maintained under anesthesia for
the same time as the IIR group in terms of duration of the
experiment.
2.3. Treatment Protocols. Forty-eight SD rats were randomly
divided into eight groups (𝑛 = 6 per group): sham, IIRmodel,
sham+Lipoxin A4 (LXA4), IIR+LXA4, sham+LXA4+Boc-
2 (Boc-2, C
44
H
59
N
5
O
8
, a LXA4 antagonist, Figure 1),
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IIR+LXA4+Boc-2, sham+LXA4+brusatol (Bru., C
26
H
32
O
11
,
a Nrf2 antagonist, Figure 1), and IIR+LXA4+Bru.
First, to evaluate the effects of Lipoxin A4 on IIR injury,
Lipoxin A4 (100 𝜇g/kg [22]) (Cayman Chemical Company,
AnnArbor, USA)was dissolved in normal saline 2mL/kg and
administrated via tail vein 15min before intestine ischemia in
IIR+LXA4, IIR+LXA4+Boc-2, and IIR+LXA4+Bru groups,
and the same dose of Lipoxin A4 was also given in sham+
LXA4 as a control. Next, to detect the role of Lipoxin A4
receptor in the protective effects of Lipoxin A4, Lipoxin A4
receptor antagonist Boc-2 (50mg/kg [23], i.p., Phoenix Phar-
maceuticals, Phoenix, AZ) was given 10min before Lipoxin
A4 administration in IIR+Boc-2 and IIR+LXA4+Boc-2
groups. Boc-2 was also given in sham+LXA4+Boc-2 as a con-
trol. Finally, to expose the role of Nrf2 pathway in Lipoxin
A4-conferred intestinal mucosa protection, Nrf2 antagonist
brusatol (0.4mg/kg [24], i.p., BOC Sciences, Shirley, NY,
USA) was administrated every other day for a total of five
times before surgery in IIR+LXA4+Bru group. Brusatol was
also given in sham+LXA4+Bru as a control.
2.4. Intestinal Mucosal Injury Scoring. Intestine paraffin
section hematoxylin-eosin staining was used for scoring.
Injury degree of intestinal mucosa was initially evaluated
independently by two pathologists who were blinded to the
study groups. Using a modified Chiu’s method [25], degree
of intestine injury was evaluated according to changes of
the glands and villus of the intestinal mucosa. A minimum
of five randomly chosen fields in intestine H&E staining
section from each rat were evaluated and averaged to evaluate
mucosal damage degree.
2.5. Sample Collection. Blood samples were collected from
abdominal aortography and centrifuged at 3,500 revolu-
tions/min (rpm) for 15min at 4∘C. The plasma was used for
subsequent measurements. A segment of 1 cm intestine was
cut 5 cm away from the terminal ileum for paraffin embed-
ding. Another segment of 4 cm was cut and washed with
cold saline, and intestinal mucosa was scraped off, dried with
suction paper, and preserved at −80∘C for further detection.
2.6. Cell Culture and Hypoxia/Reoxygenation (H/R) Protocol.
IEC-6 cells were obtained from American Type Culture
Collection (ATCC, Manassas, VA, USA) and cultured in
Dulbecco’s Modified Eagle’s Medium supplemented with 10%
fetal bovine serum and 1% penicillin/streptomycin antibi-
otics. Cells were grown at 37∘C in an atmosphere of 5%CO
2
in
air. The H/R protocol was performed as previously described
with modifications [26]. Briefly, for hypoxia, confluent cells
were incubated in an anaerobic chamber equilibrated with
5% CO
2
and 95% N
2
. A metal catalyzer (Engelhard, USA)
was used to maintain a constant low oxygen concentration
(<0.1%) in the chamber. After a 12-hour hypoxia period, cells
were transferred back to a regular incubator with 21% oxygen
for 6 hours. Control experiments were performed by omitting
hypoxia and incubating the cells for 18 hours under normoxic
conditions.
2.7. Nrf2 siRNA Transfection and Lipoxin A4 Delivery in IEC-
6 Cells. IEC-6 cells were maintained in Dulbecco’s Modified
Eagle’s Medium supplemented with 10% fetal bovine serum
and 1% penicillin/streptomycin antibiotics (5% CO
2
) at 37∘C.
Commercial Nrf2 siRNA (Santa Cruz Biotechnology) was
used for inhibition of Nrf2 expression according to the
manufacturer’s protocol. After transfectionwith nonsilencing
control siRNA and Nrf2 siRNA, cells were incubated in Dul-
becco’s Modified Eagle’s Medium for 48 hours. Each exper-
iment was performed at least in triplicate. IEC-6 cells were
collected and mRNA expression of Nrf2 level was detected
by real time Polymerase Chain Reaction using the follow-
ing primers: 5󸀠-GGTGATGAATTTTACTCTGC-3󸀠 (sense)
and 5󸀠-TTTCCGAGTCACTGATGAACC-3󸀠 (anti-sense) for
Nrf2 and 5󸀠-GTCGGTGTGAACGGATTT-3󸀠 (sense) and 5󸀠-
ACTCCACGACGTACTCAGC-3󸀠 (anti-sense) for GAPDH.
Before H/R injury, the cells in some of the subgroups were
exposed to Lipoxin A4 (10 nM) for 12 hours [27].
2.8. Enzyme-Linked Immunosorbent Assay. Diamine oxidase
(DAO) (Cloud-Clone Crop, USA), D-lactic acid (D-LA)
(Biosamite, USA), and intestinal-type fatty acid-binding
protein (FABP2) (Cloud-Clone Crop, USA) in serum were
measured according to the manufacturer’s instructions of
enzyme-linked immunosorbent assay (ELISA) kits as previ-
ously described [20].
2.9. Determination of 15-F2t-Isoprostane Content and
Superoxide Dismutase Activity. 15-F2t-isoprostane, a specific
marker of oxidative stress, was measured using an enzyme-
linked immunoassay kit as we described [28]. Homogenized
intestinal mucosa tissues were purified using Affinity Sorbent
and Affinity Column (Cayman Chemical, Ann Arbor, MI)
and then processed for analysis. The values of free 15-F2t-
isoprostane were expressed as pg/g wet protein in tissue
homogenates. The activity of superoxide dismutase (SOD)
was determined using a commercial kit (Nanjing Jiancheng
Bioengineering Institute, Nanjing, China) as we described.
SOD activity was expressed as unit/mg wet protein.
2.10. Lactate Dehydrogenase (LDH) Assay. IEC-6 cells were
seeded at low density (10,000 cells/cm2) in 96-well plates.
After experimental treatment, LDH assays, as measured for
cell injury degree, were carried out according to themanufac-
turer’s introduction (Roche Diagnostics, Indianapolis, USA)
as described in our previous study [28].
2.11. Immunofluorescence. For immunofluorescence, the intes-
tine paraffin blocks were cut into 5 𝜇m sections; potential
nonspecific staining in the sections was blocked with 5%
bovine serum albumin and 0.3% Triton X-100 in PBS. Mouse
anticytochrome C (1 : 200) (Santa Cruz, California, USA)
antibody was used as primary antibodies and then followed
by a secondary antibody conjugated with fluorescence (1 : 100)
(Life Technologies, USA). Fluorescent microscope (Leica,
DMLB2, Germany) was utilized for viewing the stained
sections. Five randomly selected fields of each slide were
semiquantified and averaged using the software Image J 1.48
(National Institutes of Health) according to its instructions.
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2.12. TUNEL Staining. Apoptosis in the intestine sections
was examined after Terminal Deoxynucleotidyl Transferase
dUTP Nick-End Labeling (TUNEL) staining with in situ cell
death detection kit (Roche, Basel, Switzerland) as previously
described [29]. The hematoxylin (Sigma-Aldrich, St. Louis,
MO) was used to stain nuclei. The average number of
apoptotic positive cells was calculated from five random
fields.
2.13. Western Blot Assay. Rat intestinal mucosa homogenate
or cell suspension was resolved by 8–10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis and transferred
to nitrocellulose membranes and processed as described
[30]. Monoclonal antibody to Nrf2 antibodies (1 : 200, sc-
722, Santa Cruz, California, USA), Keap1 antibodies (1 : 500,
ABS97, Millipore), and HO-1 (1 : 200, sc-10789, Santa Cruz,
California, USA) were used as primary antibodies, and the
HP-conjugated anti-mouse IgG (Cell Signaling Technology)
as secondary antibody. Protein bands were detected by ECL
kit (enhanced chemiluminescence detection KGP1125, Nan-
jing KeyGen Biotech. Co., Ltd.). Anti-histone H2A (1 : 1000,
Santa Cruz, California, USA) and anti-GAPDH (1 : 2000,
Merck Millipore, Germany) were used as loaded sample
reference to normalize relative level of each detected protein.
2.14. Survival Rates. Survival rates were assayed in another 4
groups (sham, IIR, IIR+LXA4, and IIR+LXA4+Bru, 𝑛 = 18
per group).The survival rates of each groupwere observed for
duration of 72 hours from the onset of intestine reperfusion
in IIR model.
2.15. Statistical Analysis. Biochemical assays were performed
in triplicate for each specific sample. Therefore, all the data
points are means of numbers that themselves are means
of triplicate measurements for these parameters. Data are
expressed as mean ± standard error of the mean. Significance
was evaluated using one-way ANOVA test (SPSS 13.0, SPSS
Inc., Chicago, III) followed by Tukey post hoc multiple com-
parisons test for unpaired values. 𝑝 < 0.05 was considered
statistically significant.
3. Results
3.1. Lipoxin A4Attenuated IntestinalMucosaDamage after IIR
Injury. As shown in Figure 2(a), normal villi were observed
in sham group, but after 45min of intestine ischemia and
6 hours (h) of reperfusion, the intestinal mucosa was
impaired, manifested as destruction ranged from extended
subepithelial with necrotic epithelial cell sheets at the tips
of the villi to denuded villi with lamina propria and dilated
capillaries exposed. Compared with sham group, modified
Chiu’s score (Figure 2(b)) was significantly increased in IIR
group, accompanied with elevation of serums DAO, DLA,
and FABP2 levels (𝑝 < 0.05, Figures 2(c)–2(e)). However,
Lipoxin A4 preconditioning significantly reduced intestinal
mucosa injury induced by IIR, evidenced as lower Chiu’s
score and serums DAO, DLA, and FABP2 levels than those
in IIR groups (𝑝 < 0.05). Furthermore, Lipoxin A4 receptor
(ALXR) antagonist Boc-2 partly reversed the protective
effects of Lipoxin A4, evidenced as worsening pathological
change and increase of Chiu’s score and serums DAO,
DLA, and FABP2 levels. These results indicated that Lipoxin
A4 preconditioning conferred protective effects against IIR
injury, which involved the activation of ALXR.
3.2. Keap1/Nrf2 Pathway Was Activated by Lipoxin A4 Pre-
conditioning in an ALXR Independent Manner. To further
explore the underlying mechanism of Lipoxin A4 precondi-
tioning, intestinal mucosa oxidative stress level was detected.
As shown in Figures 3(a) and 3(b), after 45min of intestine
ischemia and 6 h of reperfusion, oxidative stress was signifi-
cantly increased in intestinal mucosa, manifested as increase
of oxidative marker 15-F2t-Isoprostane and decrease of SOD
activity (𝑝 < 0.05 versus group sham). Moreover, Lipoxin A4
preconditioning reduced mucosa 15-F2t-Isoprostane release
and increased SOD activity with concomitant elevation of
nuclearNrf2 and totalHO-1 protein expression and reduction
of Keap1 protein expression (Figures 3(c)–3(e)). However,
after blocking the ALXR by Boc-2, no change was exhibited
in Keap1/Nrf2 pathway and the associated 15-F2t-Isoprostane
and SOD activity (𝑝 > 0.05 versus IIR+LXA4). These results
suggested that the protective effects conferred by Lipoxin A4
preconditioning were associated with Keap1/Nrf2 pathway
activation, which could be activated independent of ALXR.
3.3. Nrf2 Inhibition Reversed the Intestinal Mucosa Protective
Effects Conferred by Lipoxin A4 Preconditioning. Next, Nrf2
inhibitor brusatol was employed to determine the relation-
ship between Lipoxin A4 preconditioning and Keap1/Nrf2
pathway. As shown in Figure 4, after inhibiting Nrf2 with
brusatol before LipoxinA4 intervention, nuclearNrf2 protein
expression was significantly decreased, along with decrease
of HO-1 protein expression and increase of Keap1 protein
expression, leading to an elevation of oxidative stress, man-
ifested by increase of oxidative marker 15-F2t-Isoprostane
and decrease of SOD activity, and finally resulting in higher
Chiu’s score and worsening pathologic morphology (𝑝 <
0.05 versus IIR+LXA4). These results indicated that Lipoxin
A4 preconditioning attenuated intestinal mucosa damage
after IIR injury via activating Keap1/Nrf2 pathway and the
subsequent increase of downstream antioxidative enzyme
HO-1 protein expression.
3.4. Lipoxin A4 Preconditioning Attenuated Intestinal Epithe-
lium Cells Apoptosis and Increased Rat Survival Rate via
Keap1/Nrf2 Pathway Activation. As shown in Figure 5,
IIR significantly increased the fluorescence intensity of
cytochrome C (Figures 5(a) and 5(b)) and TUNEL (Figures
5(c) and 5(d)) positive cells in intestinal mucosa at 6 hours
after reperfusion, which was related to a low rate of survival
(40%) during 72 hours after reperfusion. In contrast, Lipoxin
A4 preconditioning could effectively reduce the fluorescence
intensity of cytochrome C and TUNEL positive cells in
intestinal mucosa and significantly increased rats’ survival
rate (68%, 𝑝 < 0.05 versus IIR). However, Nrf2 antagonist
brusatol given before Lipoxin A4 preconditioning completely
reversed the protective effects conferred by Lipoxin A4,
evidenced as higher fluorescence intensity of cytochrome C
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Figure 2: Effects of Lipoxin A4 on intestine ischemia reperfusion (IIR) injury. Representative photomicrographs (400x) showing H&E
staining of intestine (a) and Chiu’s score (b) was carried out to evaluate the injury degree; quantitative analysis using ELISAmethod was taken
to assay the concentration of diamine oxidase (DAO) (c), D-lactic acid (DLA) (d), and intestinal-type fatty acid-binding protein (FABP2) (e)
in serum. Each bar represents the mean ± SEM (𝑛 = 6 per group). ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, one-way ANOVA with Tukey test.
and TUNEL positive cells in intestinal mucosa than those
in IIR+LXA4 group (𝑝 < 0.05), associated with decrease of
survival rate (42%, 𝑝 < 0.05 versus IIR+LXA4).These results
indicated that Lipoxin A4 preconditioning could elevate
rats’ survival rate via alleviating intestinal epithelium cells
apoptosis in a Keap1/Nrf2 pathway dependent manner in rat
IIR model.
3.5. Knockdown of Nrf2 Reversed the Protection Effects of
Lipoxin A4 on Preventing IEC-6 Cells from H/R Injury. To
confirm the effects of Lipoxin A4 on intestinal epithelium
cells, an IEC-6 cells H/R model was used in our study. First,
in IEC-6 cell line, the gene knockdown effect of Nrf2 was
determined and the PCR result has shown that, after being
treated with Nrf2 siRNA for 12 hours, the mRNA of Nrf2
was significantly decreased (𝑝 < 0.01 versus siRNA vector;
Figure 6(a)). Then, we confirmed that effects of Lipoxin A4
pretreatment on IEC-6 cells exposed to H/R. Lipoxin A4
(10 nM) could dramatically decrease LDH release from IEC-6
cells compared with the control group (𝑝 < 0.01, Figure 6(b))
and elevate the Nrf2 protein expression (Figure 6(c)) which
was decreased after H/R injury. However, Nrf2 siRNA signif-
icantly reversed this protective effect, evidenced by increased
LDH release.
4. Discussion
Aberrant synthesis of reactive oxygen species and accumu-
lation of oxidative products within the intestinal mucosa are
believed to be a chief culprit for the pathogenesis of intestine
injury caused by IIR [31]. Increased levels of Nrf2 nuclear
translocation are associated with repair of injured intestinal
mucosa in animal models [32]. Here, the current study
addresses the question of whether the antioxidant effects of
Lipoxin A4 were mediated via Nrf2 pathway activation in rat
ischemia reperfusion injury model. There are several major
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Figure 3: Effects of Lipoxin A4 on Keap1/Nrf2 pathway. Quantitative analysis using ELISA method was taken to assay the concentration of
oxidative marker 15-F2t-Isoprostane (a) and SOD activity (b) in intestine mucosa. Representative Western blots and quantitative analyses
showing total Keap1 (c) and HO-1 (d) protein and nuclear Nrf2 (e) protein expressions in intestine mucosa. Each bar represents the mean ±
SEM (𝑛 = 6 per group). ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, one-way ANOVA with Tukey test. NS means no significant difference.
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Figure 4: Brusatol reversed the protective effects conferred by Lipoxin A4. Representative photomicrographs (400x) showing H&E staining
of intestine (a) and Chiu’s score (b) was carried out to evaluate the injury degree; quantitative analysis using ELISA method was taken to
assay the concentration of oxidative marker 15-F2t-Isoprostane (c) and SOD activity (d) in intestine mucosa. Representative Western blots
and quantitative analyses showing total Keap1 (e) and HO-1 (g) protein and nuclear Nrf2 (f) protein expressions in intestine mucosa. Each
bar represents the mean ± SEM (𝑛 = 6 per group). ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, one-way ANOVA with Tukey test.
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Figure 5: Lipoxin A4 attenuated intestinal epithelium cells apoptosis and finally increased rat survival rate. Representative photomicrographs
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findings in the current study. Firstly, Lipoxin A4 conferred an
antioxidative effect against intestinalmucosa injury following
IIR and protected IEC-6 cells from H/R injury, which was
mediated by enhancing endogenous Keap1/Nrf2 signaling.
Furthermore, the effect of Lipoxin A4 was developed in a
Lipoxin A4 receptor independent manner.
LXA4was identified as a short lived lipid and described as
a potent endogenous bioactive anti-inflammatory lipidmedi-
ator while its antioxidant effects have been recently reported
[14]. LXA4 may exert biological effects through binding to
ALXR. In the present study, the protective effect of LXA4
on IIR-induced intestinal mucosa injury is in principle in
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Figure 6: Effects of Lipoxin A4 and knockdown of Nrf2 on H/R-induced cell damage in IEC-6 intestinal epithelium cells. (a) Effects of
gene knockdown by Nrf2 siRNA. (b) Relative lactate dehydrogenase (LDH) release of IEC-6 cells. (c) Determining nuclear Nrf2 expression
by western blot. Bars are mean ± standard deviation from four independent experiments. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, one-way ANOVAwith Tukey
test.
line with several other studies which demonstrated protective
effects for pharmacologically delivered Lipoxins or stable
Lipoxin analogues in pathologies with I/R [33–35], and
these protective effects can be reversed by Boc-2, a specific
antagonist of ALXR [36]. Therefore, the protective effect of
LXA4 on intestinal mucosa seen in the current study may be
partly related to ALXR activation, consisted with results of
Tang et al. which showed that activating ALXR with BML-
111 could attenuate lung injury in endotoxemic mice and
mitigate endothelial hyperpermeability, while Boc-2 reversed
this effect [37]. However, Wu et al. found that the effect
of LXA4 on oxygen-glucose deprivation (OGD)/recovery-
(OGDR-) induced astrocyte injury cannot be reversed by
Boc-2, and the effect of LXA4 on astrocytic cell damage
may be not related to ALXR [38]. The difference of these
results may be related to the special pathophysiology of the
disease and the different underlying mechanisms remain to
be explored.
We recently showed that NF-E2-related factor-2 (Nrf2)
played an important role in IIR injury through regulating a
major environmental and oxidative stress response [11]. Nrf2
is held in the cytoplasm by a cytoskeletal-associated specific
inhibitory protein, the Kelch-like ECH associating protein 1
(Keap1) in normal quiescent cells.Upon stimulation by oxida-
tive stress, cysteine residues within the hinge region of Keap1
can bemodified and cause a conformational change, resulting
in the loss of Nrf2 binding [39].The Nrf2 is then translocated
into the nucleus and binds to the promoter region of a num-
ber of genes encoding antioxidative and phase 2 enzymes,
such as superoxide dismutase (SOD) and heme-oxygenase
1 (HO-1), which can antagonize oxidative stress induced by
reactive oxygen species [40]. In our current study, we found
that Lipoxin A4 preconditioning activated the transcription
factorNrf2 and subsequently increased the expression ofHO-
1, leading to reduction of apoptosis of intestinal epithelium
cells. Similarly, Lipoxin A4 has also been found to exert
antioxidative effects to ameliorate ischemic brain injury by
directly activating another transcription factor PPAR-𝛾 [19].
In addition, Lipoxin A4 could suppress lipopolysaccharide-
induced HeLa cell proliferation and migration via NF-𝜅B
pathway [41]. These suggest that Lipoxin A4 could activate
multiple signal transduction pathways to confer protective
effects in a variety of I/R disorders and that Lipoxin A4
preconditioning may be a prospective intervention in reduc-
ing intestinal mucosa injury induced by IIR. Even more
interesting is that we found Lipoxin A4 activated Keap1/Nrf2
pathway in anALXR independentmanner, indicating that the
protective effects of LipoxinA4 in IIR injurymay bemediated
by both receptor-binding and Nrf2 nuclear translocation
pathways, which could function independently.
Of note, Lipoxin A4 postconditioning also has been
reported to provide protective effects on myocardial ische-
mia/reperfusion injury [42], but whether or not it can protect
against intestinal mucosa injury induced by IIR needs to be
10 Oxidative Medicine and Cellular Longevity
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Figure 7: Proposed signaling mechanisms mediated by Lipoxin A4 in preventing intestinal epithelium cells from intestine ischemia
reperfusion (IIR) injury. Lipoxin A4 promotes Keap1 dissociation from Nrf2 and leads to Nrf2 translocation from cytoplasm to nucleus,
resulting in enhancing downstream HO-1 gene expression without binding to the Lipoxin A4 receptor (ALXR). Antioxidant enzyme HO-1
could possibly reduce cytochrome C release from mitochondria and decrease lipid peroxidative product 15-F2t-Isoprostane and elevate cell
antioxidant ability evidenced by increase of superoxide dismutase (SOD) and finally decrease cells apoptosis. In addition, Lipoxin A4 binding
to ALXR could also reduce damage of diamine oxidase (DAO) products, D-lactic acid (DLA), and intestinal-type fatty acid-binding protein
(FABP2) release with other mechanisms.
further investigation.Meanwhile, blocking LipoxinA4 recep-
tor (ALXR) using Boc-2 could aggregate intestinal mucosa
injury with concomitant increase in serums DAO, DLA,
and FABP2. This suggests that activating ALXR represents
a mechanism whereby Lipoxin A4 preconditioning confers
protection against IIR injury. However, the downstream
signaling following Lipoxin A4 preconditioning mediated
binding to ALXR with subsequent protective effects on IIR
requires future study although there was study indicating
that it may be through p38 MAPK pathway activation [43].
Moreover, Lipoxin A4 pretreatment has been shown as an
effectivemethod for preventing ischemia/reperfusion-caused
intestine injury in our current study. However, it is difficult
to predict the onset of ischemia in some clinical settings that
may cause IIR. In the further study, Lipoxin A4 treatment
will be employed at the time of reperfusion instead of
being given before ischemia, because the implementation of
intestinal protective therapy at the time of reperfusion could
be clinically feasible as it is more predictable and is under the
clinician’s control.
In summary, we have discovered that Nrf2 is involved to
serve as an antioxidant enzyme gene transcription factor in
combating intestinal mucosa injury induced by IIR. Lipoxin
A4 preconditioning could effectively attenuate intestinal
mucosa oxidative stress via activating Keap1/Nrf2 pathway
and subsequently enhance downstream antioxidant enzyme
HO-1 production, highlighting the importance of enhancing
Nrf2 nuclear translocation in IIR injury prevention. Lipoxin
A4 receptor inhibition, however, seems to have no effects
on Keap1/Nrf2 pathway. The data presented in the current
study support the notion that Lipoxin A4 preconditioning
attenuated intestine injury via activation of Keap1/Nrf2 in a
receptor independent way (Figure 7). Therefore, enhancing
the efficiency of Nrf2 nuclear translocation may provide
a novel approach for promoting the protective effects of
Lipoxin A4 intervention.
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